“…In addition to what has been discussed in the above sections, a search through SciFinder revealed a few more cases wherein the Mitsunobu reaction has been applied. These include the preparation of (i) 2-substituted 2,3-dihydro-4-quinolones by sulfonamide activated N -alkylation, (ii) entecavir, (iii) cyclic peptolides, (iv) benzothiadiazine dioxide, (v) thymine containing pseudopeptides via N -alkylation by o -Ns activation,(vi) anhydro-nucleosides from cyclization of 6-amino-7H-purine-8(9H)-thione, (vii) 5-{4-[2-(methyl- p -substituted phenylamino)ethoxy]benzyl}thiazolidine-2,4-diones by O -alkylation (ether formation), (viii) furan containing macrolactones, (ix) C(1)−C(7) and C(17)−C(28) subunits of didemnaketal A and B, respectively, , (x) prenylflavanones, (xi) boonein from bisbenzyloxymethyl-substituted bicyclo[2.2.1]ketone, (xii) pseudo-aminosugars, (+)-valienamine and (+)-validamine, (xiii) the monomethyl ether of 1,1′-binaphthol as a precursor for poly(meth)acrylates with a pendant 1,1′-binaphthyl group, (xiv) esters of syn -diisopropyl-1-bromo-2-hydroxy-2-( p -methoxyphenyl)ethylphosphonate, (xv) racemic cyclopent-3-en-1-yl nucleoside analogues, (xvi) pregnane ketols, (xvii) aminopropyl phosphonate nucleosides with purine and pyrimidine bases, (xviii) high glass transition polyimides via etherification for NLO applications, (xix) liquid crystalline aromatic azo compounds (esterification), (xx) peptide nucleic acid monomers based on N -[2-( tert -butoxycarbonylaminomethyl)- trans -4-hydroxy]tetrahydropyrrole acetic acid Me ester, (xxi) chiral liquid crystalline polyacrylates based on l -isoleucine (esterification), (xxii) 20-hydroxyhepoxilins (inversion/rearrangement), (xxiii) α-mercaptomethyl amino acids from α-hydroxymethyl amino acids, (xxiv) β-lactamase hydrolysis resistant penicillin analogues, (xxv) (3 R )-2′3′-dihydro-β,β-caroten-3-ol, (xxvi) deuterium- and tritium-labeled multidrug resistance modulator LY 335979 (etherifcation), (xxvii) acyl glucuronides of R -(−)- and ( S )-(+)-ibuprofen, (xxviii) 2,3-dideoxy-2,3-epimino and 3,4-dideoxy-3,4-epimino derivatives of 1,6-anhydro-β- d -hexopyranoses, (xxix) azaoxamacrobicyclic ligands, (xxx) tetrahydropyrido[2,1- b ]quinazolin-11-ones, (xxxi) reversed imidazole nucleosides, protected (3- N -hydroxyamino-1-alkenyl)phosphonates via BocNHOBoc, (xxxii) poly(etherimide)s with attached NLO moieties, N -(β-phenethyl)- N -triflylvaline ( N -alkylation), and (xxxiv) (−)-cladospolide B …”